What is HC Wainwright’s Forecast for Celcuity Q1 Earnings?

Celcuity Inc. (NASDAQ:CELC) – Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Celcuity in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.01) per share for the quarter, down from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at $1.50 EPS and FY2029 earnings at $3.63 EPS.

Celcuity (NASDAQ:CELC) last issued its earnings results on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.13).

Separately, Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Celcuity in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Celcuity currently has an average rating of “Buy” and an average target price of $30.17.

Celcuity Stock Performance

CELC stock opened at $8.65 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a 1-year low of $7.70 and a 1-year high of $20.15. The business has a 50-day moving average price of $10.99 and a 200 day moving average price of $12.77. The company has a market capitalization of $321.17 million, a P/E ratio of -3.31 and a beta of 0.44.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently added to or reduced their stakes in CELC. Baker BROS. Advisors LP raised its holdings in Celcuity by 42.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company’s stock worth $35,062,000 after purchasing an additional 803,575 shares in the last quarter. Soleus Capital Management L.P. grew its position in shares of Celcuity by 106.0% in the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock worth $33,577,000 after buying an additional 1,319,700 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Celcuity by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company’s stock worth $21,624,000 after acquiring an additional 24,429 shares in the last quarter. State Street Corp lifted its position in Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Celcuity by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 692,372 shares of the company’s stock valued at $9,065,000 after acquiring an additional 62,003 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.